- GlaxoSmithKline Plc’s two-drug treatment for HIV infections won U.S. market approval on Monday, boosting the British drugmaker’s growth prospects against competitor Gilead Sciences Inc.
GSK showed in drug trials last year that the once-a-day Dovato pill was as good as a standard three-drug cocktail in suppressing the virus that causes AIDS and also in terms of tolerability. “We are trying to establish a new normal for people with HIV. We absolutely believe that people living with HIV should not take more medicines than they need,” said Deborah Waterhouse, who heads the British drugmaker’s HIV unit.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Reuters - 🏆 2. / 97 Read more »